New York, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA ...

TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)--Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a pioneering company developing innovative products for the treatment of rare genetic diseases ...

Muscular dystrophy refers to a group of rare, genetic, progressive diseases that primarily affect the body’s muscles, causing them to weaken and deteriorate over time. While muscular dystrophies are ...

Designation supports development of CRD-003, an investigational therapy targeting the root cause of Limb-Girdle Muscular ...

Researchers at Yale have identified a possible treatment for Duchenne muscular dystrophy (DMD), a rare genetic disease for which there is currently no cure or treatment, by targeting an enzyme that ...

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the ...

New York, Dec. 17, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) and Coalition to Cure Calpain 3 (C3) announced today collaborative funding of a $300,000 research grant to support ...